← Back to Search

Immersive Virtual Reality for Chronic Pain

Phase 1 & 2
Recruiting
Led By Luana Colloca, MD/PhD/MS
Research Sponsored by University of Maryland, Baltimore
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
English speaker (written and spoken)
Age (18-88 years)
Must not have
Any facial trauma that has occurred in the last 6 weeks
Present or past degenerative neuromuscular disease
Timeline
Screening 3 weeks
Treatment Varies
Follow Up one session lasting from 2 to 3 hours
Awards & highlights

Summary

This trial investigates using virtual reality to help people with chronic pain from Temporomandibular Disorders (TMD). The VR experience aims to distract the brain from pain and may also trigger the release of natural pain-relieving chemicals. Researchers will compare the effects of real VR to see how effective it is. Virtual reality (VR) has been increasingly studied and used as a tool for pain management in various conditions, including chronic pain, procedural pain, and specific syndromes like complex regional pain syndrome and phantom limb pain.

Who is the study for?
This trial is for English-speaking adults aged 18-88 with Temporomandibular Disorder (TMD) for at least 3 months. Excluded are those with certain psychiatric conditions, recent substance abuse, pregnancy, color-blindness, severe facial trauma or motion sickness, and those on specific medications like antidepressants.
What is being tested?
The study explores how immersive virtual reality can manage chronic pain compared to placebo effects. It involves active VR treatment, sham VR (placebo), no intervention control groups, and the administration of Naloxone or Saline to understand pain mechanisms.
What are the potential side effects?
While not explicitly listed in the provided information, potential side effects may include discomfort from wearing a VR headset such as eye strain or nausea due to motion sickness; Naloxone might cause withdrawal symptoms in individuals dependent on opioids.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I can speak and write in English.
Select...
I am between 18 and 88 years old.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have not had any facial injuries in the last 6 weeks.
Select...
I have or had a muscle-weakening disease.
Select...
I have a history of fainting.
Select...
I have had jaw or temple pain from a toothache or infection in the last 3 months.
Select...
I have hearing problems that haven't been corrected.
Select...
I have not been hospitalized for a severe psychiatric condition in the last 3 years.
Select...
My neck pain is not due to TMD but another condition like stenosis.
Select...
I have high blood pressure or symptoms of low blood pressure.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~one session lasting from 2 to 3 hours
This trial's timeline: 3 weeks for screening, Varies for treatment, and one session lasting from 2 to 3 hours for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Ischemic pain endurance
Secondary study objectives
Ischemic pain rating

Trial Design

3Treatment groups
Experimental Treatment
Active Control
Placebo Group
Group I: Natural HistoryExperimental Treatment4 Interventions
Natural history group, where participants will not be given any drugs. Participants will be stratified for sex and then randomized to the Natural History group.
Group II: NaloxoneActive Control4 Interventions
NARCAN® Naloxone Nasal Spray will be used to determine how the opioid tone shapes VR-induced hypoalgesia. Participants will be stratified for sex and then randomized to naloxone (The dose of naloxone will be 4 mg, so 0.1 mL of 40 mg/ml naloxone solution given intranasally) or saline (0.1 mL 0.9% sodium chloride intranasally), respectively. Investigators, staff, and participants will be blinded to the treatment options.
Group III: SalinePlacebo Group4 Interventions
Saline group, where participants will be given saline solution (4mg) via an identical spray device. Participants will be stratified for sex and then randomized to saline arm (The dose of saline will be (0.1 mL 0.9% sodium chloride intranasally), respectively. Investigators, staff, and participants will be blinded to the treatment options.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Active Virtual Reality
2015
N/A
~60

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Placebo treatments often work through psychological and neurobiological mechanisms such as patient expectations, conditioning, and the release of endogenous opioids. Immersive virtual reality (VR) leverages these mechanisms by engaging and distracting patients, which can reduce their perception of pain. This is important for placebo patients because it highlights the potential of non-pharmacological interventions like VR to manage pain effectively by harnessing the body's natural pain-relief processes.
Virtual Reality in the Management of Chronic Low Back Pain: A Scoping Review.Virtual reality relaxation for the general population: a systematic review.Virtual reality for stroke rehabilitation.

Find a Location

Who is running the clinical trial?

University of Maryland, BaltimoreLead Sponsor
705 Previous Clinical Trials
378,201 Total Patients Enrolled
9 Trials studying Pain
1,740 Patients Enrolled for Pain
Luana Colloca, MD/PhD/MSPrincipal InvestigatorUniversity of Maryland Baltimore School of Nursing
1 Previous Clinical Trials
182 Total Patients Enrolled
1 Trials studying Pain
182 Patients Enrolled for Pain

Media Library

Natural History Clinical Trial Eligibility Overview. Trial Name: NCT04851301 — Phase 1 & 2
Pain Research Study Groups: Natural History, Naloxone, Saline
Pain Clinical Trial 2023: Natural History Highlights & Side Effects. Trial Name: NCT04851301 — Phase 1 & 2
Natural History 2023 Treatment Timeline for Medical Study. Trial Name: NCT04851301 — Phase 1 & 2
Pain Patient Testimony for trial: Trial Name: NCT04851301 — Phase 1 & 2
~135 spots leftby Oct 2027